Indian Journal of Private Psychiatry

Register      Login

VOLUME 18 , ISSUE 1 ( January-June, 2024 ) > List of Articles

CASE REPORT

Flunarizine-induced Depression: A Case Report with Review of Literature

Gagandeep Ahuja, Anupama Arora, Simran Gupta

Keywords : Adverse drug reactions, Case report, Depression, Flunarizine

Citation Information : Ahuja G, Arora A, Gupta S. Flunarizine-induced Depression: A Case Report with Review of Literature. Ind J Priv Psychiatry 2024; 18 (1):48-50.

DOI: 10.5005/jp-journals-10067-0164

License: CC BY-NC 4.0

Published Online: 03-01-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim and background: Flunarizine, a cerebro-selective calcium channel blocker, prescribed worldwide for migraine prophylaxis, has demonstrated efficacy and safety in different migraine types and patient populations, comparable to other first-line antimigraine drugs used for migraines such as propranolol, topiramate, amitriptyline, and valproate. Case description: A 35-year-old female primarily came to the outpatient department for treatment of headache and was started on Flunarizine 10 mg. Her headache significantly reduced but after 8 weeks she reported complaints of low mood, reduced sleep, reduced appetite, loss of interest in work, and crying spells. She was treated with adequate doses of Sertraline but showed no improvement in symptoms. Mental status examination revealed depressed affect, anhedonia, and negative cognition. After ruling out organic causes and medical work-up, drug-induced depression was considered, and flunarizine was stopped, and Sertraline was continued at the same dose. After she reported an improvement in depressive symptoms, the diagnosis was changed to drug-induced depression. Conclusion: Flunarizine may induce depressive symptoms in susceptible patients. Patients receiving long-term flunarizine should be regularly monitored for any signs of depression. If a patient develops symptoms indicative of depression after the initiation of a given agent; another agent should be considered. Clinical significance: As a clinician, we can never be too cautious of the adverse reactions of the prescribed drugs, hence, we should always be vigilant and prepared if the situation ever arrives.


PDF Share
  1. Celano CM, Freudenreich O, Fernandez-Robles C, et al. Depressogenic effects of medications: A review. Dialogues Clin Neurosci 2011;13(1):109–125. DOI: 10.31887/DCNS.2011.13.1/ccelano.
  2. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes care 2001;24(6):1069–1078. DOI: 10.2337/diacare.24.6.1069.
  3. Cohen SD, Norris L, Acquaviva K, et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007;2(6):1332–1342. DOI: 10.2215/CJN.03951106.
  4. Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr 2004;2004(32):32–39. DOI: 10.1093/jncimonographs/lgh026.
  5. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003;54(3):227–240. DOI: 10.1016/s0006-3223(03)00587-0.
  6. Olesen J. International classification of headache disorders. Lancet Neurol 2018;17(5):396–397. DOI: 10.1016/S1474-4422(18)30085-1.
  7. Zimmerman M, Martinez JH, Young D, et al. Severity classification on the Hamilton depression rating scale. J Affect Disord 2013;150(2): 384–388. DOI: 10.1016/j.jad.2013.04.028.
  8. Pompili M, Di Cosimo D, Innamorati M, et al. Psychiatric comorbidity in patients with chronic daily headache and migraine: A selective overview including personality traits and suicide risk. J Headache Pain 2009;10(4):283–290. DOI: 10.1007/s10194-009-0134-2.
  9. Torelli P, Lambru G, Manzoni GC. Psychiatric comorbidity and headache: Clinical and therapeutical aspects. Neurol Sci 2006;27: s73–s76. DOI: 10.1007/s10072-006-0574-2.
  10. Casucci G, Villani V, Finocchi C. Therapeutic strategies in migraine patients with mood and anxiety disorders: Physiopathological basis. Neurol Sci 2010;31(Suppl 1):99–101. DOI: 10.1007/s10072-010-0296-3.
  11. Finocchi C, Villani V, Casucci G. Therapeutic strategies in migraine patients with mood and anxiety disorders: Clinical evidence. Neurol Sci 2010;31(Suppl 1):S95–S98. DOI: 10.1007/s10072-010-0297-2.
  12. Sørensen PS, Larsen BH, Rasmussen MJ, et al. Flunarizine versus metoprolol in migraine prophylaxis: A double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;31(10):650–657. DOI: 10.1111/j.1526-4610.1991.hed3110650.x.
  13. Dhondt TD, Beekman AT, Deeg DJ, et al. Iatrogenic depression in the elderly: Results from a community-based study in the Netherlands. Soc Psychiatry Psychiatr Epidemiol 2002;37(8):393–398. DOI: 10.1007/s00127-002-0573-4.
  14. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug saf 2007;30(7):555–567. DOI: 10.2165/00002018-200730070-00001.
  15. Mula M, Hesdorffer DC, Trimble M, et al. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009;50(5):1072–1076. DOI: 10.1111/j.1528-1167.2008.01799.x.
  16. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44(5): 659–663. DOI: 10.1046/j.1528-1157.2003.05402.x.
  17. McNeil GN, Shaw PK, Dock DS. Substitution of atenolol for propranolol in a case of propranolol-related depression. Am J Psychiatry 1982;139(9):1187–1188. DOI: 10.1176/ajp.139.9.1187.
  18. Oppenheim G. Propranolol-induced depression: Mechanism and management. Aust N Z J Psychiatry 1983;17(4):400–402. DOI: 10.1080/00048678309160022.
  19. Thiessen BQ, Wallace SM, Blackburn JL, et al. Increased prescribing of antidepressants subsequent to ß-blocker therapy. Arch Intern Med 1990;150(11):2286–2990. PMID: 1978648.
  20. Ko DT, Hebert PR, Coffey CS, et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288(3): 351–357. DOI: 10.1001/jama.288.3.351.
  21. Verbeek DE, van Riezen J, de Boer RA, et al. A review on the putative association between beta-blockers and depression. Heart Fail Clin 2011;7(1):89–99. DOI: 10.1016/j.hfc.2010.08.006.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.